Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Muscular Atrophy

Muscular Atrophy — NIH Grants & Funding

Active and recent NIH-funded research on Muscular Atrophy. Data from NIH RePORTER, last 36 months.

MONDO:0004323

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Muscular Atrophy has a robust NIH research funding landscape with 48 funded grants and $30.3M in total funding over the period.

48funded grants from NIH

Portfolio: $21.1MCumulative: $30.3M39 active9 completed47 PIs38 institutions

6 new grants started in the last 12 months.

By Research Theme

Basic Science

Translational

Gene/Cell Therapy

Clinical

Epi / Nat. History

Biomarker / Dx

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$3.1M

FY22

$2.9M

FY23

$2.7M

FY24

$17.9M

FY25

$3.7M

FY26

By Funding Mechanism

R01

R21

F31

K99

R35

F30

Adjacent Research(89 grants)

These grants mention Muscular Atrophy as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(89)

OtherRF1Active

Targeting a novel inter-tissue L-BAIBA/FGF23 axis to enhance adaptive musculoskeletal remodeling in aging

WHITE, KENNETH et al.·INDIANA UNIVERSITY INDIANAPOLIS·INDIANAPOLIS, IN

$3,126,515 (FY2025)

NIH RePORTER

OtherP01Active

Kynurenine accumulation drives loss of muscle and bone function with aging

ISALES, CARLOS·AUGUSTA UNIVERSITY·AUGUSTA, GA

$2,218,187 (FY2025)

NIH RePORTER

OtherP01Completed

The role of the macroenvironment in pancreatic cancer-induced cachexia

Guttridge, Denis·MEDICAL UNIVERSITY OF SOUTH CAROLINA·CHARLESTON, SC

$1,855,958 (FY2025)

NIH RePORTER

OtherR01Active

Targeting Myofiber NAD(P)H Oxidases in Sepsis-Induced Myopathy

Laitano, Orlando·UNIVERSITY OF FLORIDA·GAINESVILLE, FL

$1,829,773 (FY2025)

NIH RePORTER

OtherU01Active

Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1)

Johnson, Nicholas·VIRGINIA COMMONWEALTH UNIVERSITY·RICHMOND, VA

$933,443 (FY2025)

NIH RePORTER

OtherR44Active

Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity

Simao, Fabricio et al.·QUIVER BIOSCIENCE INC.·CAMBRIDGE, MA

$862,420 (FY2025)

NIH RePORTER

OtherU01Active

Clinical Trial Readiness for Children 0-5 years with Congenital Muscular Dystrophy Secondary to LAMA2 Mutations

Connolly, Anne·RESEARCH INST NATIONWIDE CHILDREN'S HOSP·COLUMBUS, OH

$857,429 (FY2025)

NIH RePORTER

OtherR01Active

Changes in Body Composition including Muscle with Anti-Obesity Medications, both with and without Exercise

Jakicic, John et al.·UNIVERSITY OF KANSAS MEDICAL CENTER·KANSAS CITY, KS

$789,684 (FY2025)

NIH RePORTER

OtherR01Active

Novel cardiopulmonary exercise testing variables to differentiate neuromuscular deconditioning from disease

Rossiter, Harry·LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER·TORRANCE, CA

$785,006 (FY2025)

NIH RePORTER

OtherR01Active

Remotely Monitored, Mobile health-supported High Intensity Interval Training after COVID-19 Critical Illness (REMM HIIT-Covid19)

Pastva, Amy et al.·DUKE UNIVERSITY·DURHAM, NC

$783,550 (FY2025)

NIH RePORTER

NIH Grants & Funding for Muscular Atrophy | Kisho | Kisho

Kisho

Muscular Atrophy — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Adjacent Research(89 grants)

Other(89)

Targeting a novel inter-tissue L-BAIBA/FGF23 axis to enhance adaptive musculoskeletal remodeling in aging

Kynurenine accumulation drives loss of muscle and bone function with aging

The role of the macroenvironment in pancreatic cancer-induced cachexia

Targeting Myofiber NAD(P)H Oxidases in Sepsis-Induced Myopathy

Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1)

Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity

Clinical Trial Readiness for Children 0-5 years with Congenital Muscular Dystrophy Secondary to LAMA2 Mutations

Changes in Body Composition including Muscle with Anti-Obesity Medications, both with and without Exercise

Novel cardiopulmonary exercise testing variables to differentiate neuromuscular deconditioning from disease

Remotely Monitored, Mobile health-supported High Intensity Interval Training after COVID-19 Critical Illness (REMM HIIT-Covid19)

Top Funded Institutions

Top Principal Investigators